Third-generation EGFR tyrosine kinase inhibitor tablets for non-small cell lung cancer with T790M mutation. Prescribed in pulmonary oncology practices. Innovative pharmaceutical suppliers provide to specialty pharmacies and cancer centers for targeted therapy procurement.